Filed by Cardinal Health, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
Subject Company: Syncor International Inc.
Commission File No. 000-08640
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 1
CARDINAL HEALTH
MODERATOR: STEVE FISCHBACH
OCTOBER 22, 2002
8:30 AM CT
Operator: Good morning. My name is David and I will be your conference
facilitator today.
At this time I would like to welcome everyone to the Cardinal
Health first quarter earnings conference call. All lines have
been placed on mute to prevent any background noise. After the
speaker's remarks there will be a question and answer period.
If you would like to ask a question during this time simply
press star then the number one on your telephone keypad. If you
would like to withdraw your question press the pound key. Thank
you.
Mr. Fischbach you may begin your conference.
Steve Fischbach: Good morning and thanks for joining us today.
Today we will discuss Cardinal Health's fiscal 2003 first quarter
results. The portion of our remarks will be focused on the
business segment attachment of our
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 2
earnings release. If you don't have a copy of that release, you
can access it over the Internet at the Investor Center at
www.cardinal.com.
Speaking on our call today will be Bob Walter, Chairman and
Chief Executive Officer and Dick Miller, Chief Financial
Officer. After their formal remarks, we will open the phone
lines for your questions where we will have available Jim
Millar, President and Chief Operating Officer of Pharmaceutical
Distribution and Medical Surgical Products and George Fotiades,
President and Chief Operating Officer of Pharmaceutical
Technologies and Services. As always, as we get the questions,
we ask that you limit yourself to one question at a time.
Before we begin, please remember that today's call may include
forward-looking statements which are subject to risks and
uncertainties which could cause actual results to differ
materially from those projected or implied. The most significant
of those are in Cardinal's Form 10-K and 10-Q reports and
exhibits to those reports. Cardinal undertakes no obligation to
update or revise any forward-looking statement.
In connection with Cardinal Health's proposed acquisition of
Syncor International, information regarding the identity of the
persons who may be deemed to be participants in the solicitation
of Syncor stockholders is set forth in schedule 14A as filed with
the SEC by Syncor on June 14, 2002.
In connection with the proposed acquisition, Syncor has filed a
definitive proxy statement and has mailed that proxy statement to
its stockholders and Cardinal Health has filed a related
registration statement. Investors and stockholders of Syncor are
urged to read the definitive proxy statement carefully, because
it will contain important information about Cardinal Health,
Syncor and the proposed acquisition. Free copies of those
documents are
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 3
available from the SEC and can also be obtained from Cardinal
Health and Syncor.
At this time, I would like to turn the call over to Bob Walter
to begin today's discussion.
Robert Walter: Good morning.
The financial momentum that Cardinal Health experienced last
fiscal year has continued into the first quarter for fiscal '03.
The results we will discuss today came in as we expected and
they're outstanding, outstanding.
Let me start by reminding you of a few things. First of all, this
the 77th quarter in a row that I've personally reported to the
market on our results. In each we have met or beat guidance. This
is the start of our 16th year in which we have reported earnings
per share growth of 20% or greater with rising returns on sales
and capital. Frankly it was a wonderful quarter, but there were
no blockbuster deals, initiatives, announcements or one-time
events, just great solid performance.
Of course there were highlights like the performance of our
Pharmaceutical Distribution and Provider Service segment and the
Automation and Information Services segment but it was just good
performance without. We have diverse earnings sources all focused
on health care with good visibility with no major concentration
with any one customer or business segment so you might say it was
business as usual. We delivered what you expected and equally
important, what our customers and Cardinal Health associates
expected. I suppose that is the exciting part of the Cardinal
Health story. We deliver what you expect and you have good
visibility to the future.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 4
Now don't take my lack of superlatives as indicative of lack of
excitement about the future. I'm feeling great about our
history, or about our industry, about how we are positioned, the
adequacy of resources and the opportunities we are pursuing.
We have a leading market position in every one of our businesses.
We have a broader offering than our competitors and more
resources.
Dick will provide the financial details and segment results, but
I want to point out up front is something that has been the
hallmark of our quarterly earnings announcements, record breaking
results across the businesses. In fact we broke all of our
previous first quarter records in the key consolidated metrics.
Earnings per share rose 22% to 67 cents. Operating revenues up to
11.4 billion, up 16%. Operating earnings were $486 million, up
18%. At the same time return on sales, committed capital and
equity were also new records. We accomplished all of this while
keeping our net debt to capital at only 17% and executing a
pre-announced stock buyback program and continuing to reinvest
significant cash back into our businesses.
We have a strong business model, we focus on execution and we
continue to reinvest for the future. Our strong business model
starts with solid core industry economics and a superior
competitive position for Cardinal within the industry. The
industry has attractive growth and returns. Our strategy has been
built, has been to build a wide range of services to our
customers, both manufacturers and providers of healthcare. This
is paying off. We sit between a highly fragmented group of
manufacturers and providers and we have an exceptionally unique
vantage point from which to develop customized solutions for
customer's issues.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 5
The competitive position of each of our businesses continues to
strengthen. In each area, we are improving the scope and scale
of what we do and extending our profitability advantages. We
have leading market positions, which is reflected in our
superior returns on sales and capital at each of our businesses.
Cardinal offers its customers so many unique proprietary products
and services by which they each create tremendous value yet the
additional advantage is that we pull together these unique
offerings to create value for the customer.
Focusing on integration of our business is starting to show some
interesting momentum. We had more than 120 corporate service
agreements in place with providers of healthcare that combine
multiple Cardinal Health services, representing over $1.5 billion
in annual volume. Most of those agreements combine at least three
Cardinal Health services. In the future, we will begin reporting
on our successes in bundled offerings in our Pharmaceutical
Technology service area for the pharmaceutical manufacturer.
A specific integration opportunity that in my opinion will be
significant is the pending acquisition of Syncor International,
the leader in nuclear pharmacy services. Nuclear pharmacy by
itself is a great business but frankly there are other
potentially huge benefits and that is in providing manufacturers
a more effective way to get unique pharmaceuticals to market. PTS
sales and marketing capabilities will play a big role in
realizing this potential.
This acquisition is expected to close shortly after the vote of
Syncor shareholders on November 19. Incidentally Syncor's core
nuclear pharmacy business along with Cardinal/s nuclear pharmacy
business are performing exceedingly well.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 6
In the coming months we will be more aggressive about
articulating the full value of Cardinal Health to our customers.
You received a little glimpse of that approach in the Annual
Report where we talked about ourselves in terms of broad
capabilities not just company products and services. The
new logo also signals a shift in the Cardinal Health brand.
We are going to market in the future under one name, one
brand, Cardinal Health. You'll hear more about that very soon.
A second core element of our business success is execution. While
our business model makes sense we still must execute. We have
been doing that for a long time a couple of basis points
improvement at a time. This quarter's results reflect that focus.
Operational improvements are going well. Three significant
examples are the integration of Bindley Western almost 18 months
ahead of our original plan and with synergies ahead of target.
Secondly, the reorganization of the Medical Products and Services
segment which is delivering significant improvements in cost and
third example is the change in business model at Pyxis to a
build-to-order scene which has improved both margins and cost
structure. All three of these initiatives are delivering
significant improvement. So it isn't just getting more sales it's
also about converting existing sales levels to a higher
profitability.
The third part of our business strategy is reinvestment. This
quarter we invested another $25 million out of current operating
earnings on strategic projects that will help pave the way for
the future. You will see some exciting new product introductions
in both our automation and medical surgical businesses over the
next few months all of which are possible because we've invested
in product development in past years.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 7
Our capital expenditures this quarter were $70 million and that
was necessary to keep our physical facilities and information
technology productive and technologically current. We are
investing for the future there also.
Our cash flow is superb. We will continue to invest in our
current operations, acquisition opportunities and repurchase
stock. From my perspective in looking at acquisitions as long as
it's strategic, economic and cultural fits are right we're
looking, but acquisition must add value for our customers and we
do have the management capacity to absorb additional operations.
Overall, this quarter was a continuation of the themes of the
past. solid business fundamentals combined with execution and
follow-on adjusting. I'm really pleased about where the
businesses are right now.
I'll now turn this over to Dick for further details on the
financial and business highlights.
Richard Miller: Okay. Thank you Bob.
I'd like to echo Bob's sentiments regarding this quarter's
results. As demonstrated by our numbers, particularly
during these unsettling economic times, the company continues its
long-standing tradition of delivering exceptional financial
performance.
Before I get into the quarter I thought I might update you on
just a few matters that were open when we reported our last
quarter's results.
First of all we have filed our 10-K with a clean audit opinion
from Ernst & Young. Secondly, (Bob) and I have filed our initial
certifications attesting to the accuracy of our reported results
and then thirdly we have completed the
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 8
SEC's review of Cardinal's filings as part of the Syncor
registration statement process. As expected all these items were
completed on time and without incident.
Now let me turn to the quarter.
Cardinal has once again delivered an outstanding, record breaking
quarter to start our new fiscal year. Today I'd like to share
with you my perspectives on the results for the quarter, review
our balance sheet and cash flow performance, provide some
comments on each of the business segments and then confirm our
outlook for the remainder of the year.
Let me remind you that beginning with this quarter all financial
information is reported on an apples to apples comparison
considering the impact of adopting FASB Statement 142 at the
beginning of last year, our fiscal year 2002. Simply put we now
have no goodwill amortization in either of the periods presented
and our gross numbers are just those that are reported.
Additionally, all my remarks exclude the impact of special items
which are comprised primarily of merger-related charges incurred
in the current period as a result of our prior acquisitions,
mainly Bindley.
Let me first look on a consolidated basis.
I'm pleased to report that the company once again generated the
exceptional financial results that our shareholders, customers
and employees have come to expect. Some key observations; our
operating revenues increased 16% driven by increases across each
of our business segments with exceptional performance from the
Pharmaceutical Distribution and Provider Services and Automation
and Information segments. Productivity management, which is a
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 9
hallmark of our business model, delivered exceptional operating
earnings leverage resulting in a first quarter record return on
sales of 4.26%. Our expenses only increased 4% on 16% revenue
growth and we're basically flat in terms of absolute dollars in
our two largest segments. Our earnings per share rose 22% during
the quarter exceeding our guidance of growing earnings per share
by 20% annually.
While these results are impressive they are not at the expense of
growths to be generated in the future. As Bob mentioned
investment spending for future growth continues with
approximately $25 million of the current quarter's operating
earnings reinvested to fund R&D and strategic business
initiatives across the organization. Our confidence in the
strength of our financial performance is further demonstrated in
our commitment to deploy a total of over $100 million in
investment spending during this fiscal year.
In addition to our investment spending we also spent over $70
million for capital addition primarily focused on increasing our
operational scale and efficiency as well as keeping our IT
systems updated. You should expect to see our capital
expenditures continue at about this level throughout the year as
we continue to reinvest in our businesses.
The combination of our outstanding earnings performance and our
focus on leveraging capital deployed in each of our businesses
culminated in record first quarter return on committed capital of
33%. That's a 340 basis point improvement from the prior year.
Focused, execution and attention to detail is a Cardinal
tradition and has long been ingrained into our business
model. This philosophy drives strong asset management and
working capital efficiency across the company. That
resulted in increasing inventory turns in the quarter and
first quarter record
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 10
lows in receivable days of only 19 days and first quarter record
low net debt to capital ratio of only 17%. Our return on equity
increased 70 basis points from the prior year period to a first
quarter record of 19% which is particularly compelling
considering the company's low debt levels.
At September 30 our balance sheet remains as strong and
conservatively positioned as it has ever been. The company used
operating cash of only $14 million for the quarter. That's an
improvement of $467 million from the prior year period despite
this being a period when you might expect to see a seasonal use
of cash.
While our receivables increased during the quarter by $259
million that's only an 11% increase in a quarter when revenues
grew 16%. Especially notable were declines in our days sales
outstanding in both the Pharmaceutical Distribution and Provider
Services and the Medical Surgical Product and Services segment.
On the inventory side we actually reduced inventory levels by 111
million during the quarter. This was driven by three factors.
First, as we have continued integrating Bindley operations we
have consciously focused on reducing safety stock levels and
achieving working capital synergies from the merger. Our
investment in large scaleable facilities has allowed us to absorb
the Bindley operation and free up working capital through
economies of scale. I ask you to recall that at the time of the
merger, which was less than two years ago, our combined company
had 41 pharmaceutical distribution facilities. Today that number
has been reduced to 28.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 11
Secondly, as we expected the shift from branded to generic
pharmaceuticals has reduced our investment in inventory. We
estimate that the fact, that the effect of the transition that
occurred in the current quarter allowed us to reduce the dollar
value of our inventory investment by about $500 million. This is
all part of the reason why the shift to generics is good for our
business.
And a third reason is that there are just general timing issues
around when inventory gets received and paid for.
We remain confident in our ability to deliver between 900 million
and $1 billion of operating cash flow for the full fiscal year
consistent with our previous guidance. In summary our balance
sheet and capital capacity is well positioned to continue to be a
competitive asset for our business strategy.
Recognizing the value that a properly executed share repurchase
program can deliver to our shareholders, the company continued
its investment strategy of repurchasing stock. During the current
quarter, approximately 6.6 million shares were repurchased having
an aggregate cost of approximately $393 million which averages
out to less than $60 per share. As of September 30, approximately
$280 million remains available under our currently authorized
share repurchase program and over the past 12 months we've
repurchased 11.7 million shares having an aggregate cost of
approximately $720 million.
Now let me turn to the segments. While the consolidated results
certainly deserve the limelight here, they are made all that more
impressive by the fact that they were achieved as the result of
strong balanced performance in all of our business segments. I've
often said that it's not just the numbers but the underlying
quality of the earnings that needs to be considered. Let me give
you some highlights that will emphasize that.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 12
Let me start our segment discussion with Pharmaceutical
Distribution and Provider Services, which represents 51% of the
company's operating earnings. This segment experienced strong
revenue growth of 17% during the quarter, which was leveraged to
21% operating earnings growth and a first quarter record return
on sales of 2.86%.
Some of the highlights would include; we had strong revenue
performance driven by 19% growth in our chain store and 25%
growth in our alternate care customer classes. The chain store
and alternate care customers are approximately 47% and 27% of our
distribution customer mix respectively. Continued revenue growth
of these customers who reside in the fastest growing segments of
the market coupled with the operating expense leverage afforded
to us by serving them will be a primary driver of operating
earnings growth for this segment. Gross margins continue to be
favorably impacted by vendor margin programs offset by the
selling margin impact of the continued shift to larger customers.
The Bindley merger continues to pay synergy dividends. While
expense synergies continue to benefit our cost structure
contributing to a first quarter record low SG&A rate of just
2.06% we're also achieving significant capital synergies by
integrating our operations. When combined with the capital
efficiency generated by the switch to generics and our continued
focus on asset management, we were able to hold our committed
capital flat compared to a year ago and drive our return on
committed capital to an all time record 34.7% in this segment.
Let me now move to the Medical Surgical and Products, Medical
Surgical Products and Services segment, which represents 27% of
our operating earnings. This segment generated a healthy 6%
revenue increase for the quarter, which was leveraged to 10%
operating earnings growth and a first
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 13
quarter record return on sales of 8.70%. The highlights for this
segment would include our self manufactured products represented
approximately 34% of the revenue mix for the quarter and grew at
a slightly slower pace than the growth experienced in
distribution. This is a typical trend that we see when we're
adding new distribution business with our strategy of increasing
the self manufactured products as the customer relationship
matures.
The reorganization in this segment that we announced in the
fourth quarter last year has had a positive impact on expense
leverage within the segment. This as well as other productivity
improvement drove our SG&A expense ratio to a record low 12.21%.
The expense salaries in this segment actually declined by nearly
$2 million versus last year.
While we see the overall market growth rate from Medical Surgical
remaining in the mid single digits, the combination of continued
strong demand for higher margin self manufactured products, cross
selling opportunities with other Cardinal businesses and
continued productivity enhancements will allow us to increase the
earnings growth rate in this segment as the year progresses
consistent with our prior guidance.
Let me next deal with Pharmaceutical Technologies and Services
which represents 13% of the company's operating earnings. This
segment delivered strong revenue growth of 18% during the
quarter. The segment continues to embrace the Cardinal Health
brand by quickly integrating strategic acquisitions and executing
a cohesive go-to-market strategy.
Some of the highlights for the quarter; sterile manufacturing,
development and analytical services as well as sales and
marketing services continue to perform well. We're very
confident and excited that the strategic investments made in
this segment will drive significant opportunities in the future.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 14
The impact of the business and product mix caused upward trends
to occur in both our gross margin and expense ratios, however our
return on sales stayed relatively flat. As expected the timing of
the launch of certain pipeline products and the staging of
performance for certain strategic investments in this segment
will cause the first half of the fiscal year to be slow relative
to the second half. We continue to expect earnings growth to
exceed 25% for the full fiscal year.
The integration of Magellan Labs and Boron LePore, both of which
were just acquired in the fourth quarter last year, is proceeding
very well. Both of these businesses made a positive contribution
to earnings in the current quarter. Since these were purchase
acquisitions they also contributed to the growth experienced by
the segment.
Our reported 16% operating earnings growth was negatively
affected by the impact of a net one-time benefit in the first
quarter a year ago. That was primarily related to a pricing
adjustment for claims against vitamin manufacturers for amounts
overcharged in prior years. This negative impact was offset by
the additional earnings from Magellan and Boron LePore in the
current quarter, such that on a fully adjusted basis the organic
growth rate remained at 16%.
Last but certainly not least is our Automation and Information
Services segment which represents 9% of the company's operating
earnings. This segment had a fantastic quarter with strong
revenue growth of 24% which was leveraged up to 55% operating
earnings growth and a first quarter record return on sales of
34.51%.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 15
The key highlights in this segment revolve around the operational
changes we made. As a point of reference remember that it was a
year ago that we implemented the operational improvements at
Pyxis which included changing to a made-to-order manufacturing
process and streamlining sales and customer service processes. As
I look back at that decision, which fundamentally changed the way
we operate and control this business, it was clearly a great
decision for our people, our customers and our shareholders.
When we announced the change last year we estimated that the
impact would be an improvement in our return on sales of 115
basis points. That was split between 55 basis points of margin
improvement and 60 basis points of expense reduction. I'm happy
to report that we are well exceeding those expectations.
To illustrate that point we need to look no further than the
current quarter. Gross margins aided by a strong product mix
increased 394 basis points while operating expenses declined 308
basis points. Importantly the improvements don't stop with our
profitability. The changes we have made have also contributed to
enhanced working capital management with lower investments in
receivables and inventories which yielded improvements in our
return on committed capital to 27.1% versus 20.3% last year.
Pyxis is the pioneer in use of automation in the hospital and
they continue this legacy of innovation in the new products and
enhancements that they bring to the market. Their innovative and
proprietary products and service offering coupled with the
chronic shortage of healthcare professionals and the urgent need
for patient safety initiatives to reduce the incidents of
medication errors will continue to be the primary driver to
future growth in this segment.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 16
In closing I'd just like to comment on our outlook for the rest
of the year. We finished our fiscal 2002 with a lot of momentum
throughout our businesses and we've seen that momentum manifest
itself in our outstanding first quarter results. While the
overall economic situation continues to be unpredictable we
believe that the healthcare industry in general and our place in
that industry specifically give us an extremely positive position
for the future.
We enter the second quarter with a great deal of confidence in
our ability to continue to deliver the consistent balanced
financial performance that you have come to expect from Cardinal.
We remain comfortable with the guidance for the year that we
provided during our August Investor Conference. That calls for
20% earnings per share growth supported by strong growth in
performance in each of our operating segments along with rising
returns on sales and capital with continued investment spending.
Thank you for your attention. Operator we'd now like to open the
call up for questions.
Operator: Thank you.
Ladies and gentlemen at this time I would like to remind everyone
in order to ask a question please press star then the number one
on your telephone keypad. We'll pause for just a moment to
compile our Q&A roster.
Your first question comes from Robert Willoughby of Credit
Suisse First Boston.
Robert Willoughby: Thank you. Bob or Dick I guess the, you did about a
billion dollars in cash from operations last year. The guidance
is for that range again this year despite what should be stronger
earnings and $465 million (unintelligible)
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 17
cash flow in the first quarter, you know, where is the big spend
on cash flow coming here going forward?
Man: I think Bob.
Robert Walter: Well Bob, we're obviously headed where we thought we would be
which is good news so, the, and some of that swing Bob is just
timing of investment in inventory. But our cash flow is coming
in better than what we thought at this point and so, you know,
we might have good news in terms of cash flow at, by the time
we get to the end of the year, you know.
I think accounts receivable management is really excellent and,
you know, the two big participants there because that's where the
big dollar volume is is Pharmaceutical Distribution and Medical
Surgical side so, you know, we're executing there well. We're
realizing savings in inventory management as we consolidate
facilities and so that's a positive but, you know, we feel
strongly about meeting or exceeding what we laid out in terms of
what our cash flow was, projections.
Dick anything else you want to add?
Richard Miller: Yes I, the only thing I'd add to that Bob would be just
a reminder that last years numbers did have about $150 million
benefit from the Pyxis securitization.
Robert Willoughby: Okay.
Richard Miller:That we did last year that's not included in our guidance for the
current fiscal year and then the other thing that we have that
just, you know, changing,
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 18
changes every year is just the timing of some of our tax payments
and some of our deferred tax turnaround.
Robert Walter: But, you know, I think we've been talking a lot about our rising
returns and our rising returns are turning in excellent asset
management and just turn it into great results. And so you'll see
terrific performance on the cash side for the year.
Next question.
Operator: Your next question comes from Larry Marsh of Lehman Brothers.
Larry Marsh: Thanks Bob, good morning. I just wanted to maybe follow-up a
bit. Dick you did a good job of breaking down the components
of, you know, why there wasn't the typical build in inventories
from June to September with that maybe you'd elaborate a little
bit more about that. How much, you know, of an impact on your
cash flow was the total switch of, to generics and, you know, are
we going to see any more benefit in terms, you know, inventory
build with further reduction in Bindley safety stock? And then,
you know, would we anticipate them building inventories toward
the end of the calendar year in Q2 so it would be a cash user in
Q2 and then the traditional pattern in the second half. I'm just
wondering if the seasonality of cash flows has changed a little
bit or is this just a particularly good quarter, if you'd
elaborate on that.
Robert Walter: Well let me turn over to Dick but, you know, as I said to you
we're performing well and we're headed where we thought we would
be.
Larry Marsh: Right.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 19
Robert Walter: There is a little bit of seasonality, I mean, you're, there's
always a little bit of timing and Dick said that in his comments
that, you know, it's not exactly predictable in, you know,
between quarters. But overall I don't see a change in our
patterns, sense a change in our patterns other than I see general
improvement in our cash flow, you know, we've, the same as on the
expense side we're getting more efficient on the expense side,
you know, we are getting even better on the asset management
side.
Dick you want to comment on that?
Richard Miller:Yes. Yes I guess Larry in terms of your question about the
impact of the generic switch in the quarter, you know, it's
difficult to predict with absolute accuracy but just based on the
increase in generics as a percentage of our overall inventories
we estimated that that impact was about $500 million in the
September quarter. Now, you know, depending on to the degree of
additional switching and levels of generics versus the remainder
of the inventory during the rest of the year, you know, there
could be some additional future impact there as well. You know we
would anticipate, you know, to, you know, probably build
inventories in the December quarter as you've seen in the past.
Robert Walter: But Larry we've, I think we've seen the most of this stuff at
the August quarter. It's come in better than we thought. I think
the generic...
Larry Marsh: Right.
Robert Walter: ...formula most people have focused on gross margin, the
impact of gross margin percentages in generics but we've also
been trying to talk about, you know, that our investments less,
our investment in receivables is less and less in inventory is
important to the generic program. It's just that it's becoming
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 20
significant because the switch outs are so big right now. So we
try to give you a little flavor and when you get to be the size
we are it's a, you know, I think Dick cited it's almost a half
a billion dollar impact. Jim any comments from your standpoint
on inventory levels or build, anything unusual you're seeing?
James Millar: I think it's, again it's the Bindley consolidation and also we
can't forget about the receivable side of the equation because
we've got less capital tied up there.
Robert Walter: Next question.
Operator: Your next question comes from Chris McFadden of Goldman
Sachs and Company.
Chris McFadden: Thanks, good morning. Nice quarter everyone. Could we
drill down a little bit...?
Robert Walter: Hey Chris we're having trouble hearing you.
Chris McFadden: Okay. Is this a little bit better?
Robert Walter: A little bit, yes.
Chris McFadden: Okay. Could we drill down a little bit on the Med Surg
business, you know, two of your larger competitors in that
segment have been reporting, you know, less than ideal results. A
slower revenue growth than you've reported, not as strong in some
of the key operating trends. I was interested in an update on
what you see is going on in that market and how you expect to
think
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 21
about the alternate site channel as you move through the balance
of '03? Thanks.
Robert Walter: Hey let me see if I can field that pieces of it on the Med Surg
side. One, we're just doing better, I mean, that's obviously
there's only, there's three major competitors in that market
place and if we do better there's only so much business to go
around and so we outgrew them on the top line. We have been
performing extremely well for a long period of time and Med Surg
frankly, you know, our 10% operating earnings improvement isn't
up to what we expect to be go forward. I think you'll see that
getti even better.
Let me let Jim kind of pick up and say a few things that he may
want to talk about on the Med Surg side.
James Millar: Yes Chris the revenue line is certainly, we're pretty impressed
with that and we feel that our cross selling initiative
are paying us big returns in terms of our corporate sales.
I think the other side of it from an operating earnings
standpoint is we took a charge for restructuring at the end of
the fourth quarter for this business and you start seeing it in
the results of the expenses and we've got, we think we're
positioning the business on a go-forward basis in a better
position on the cost side of it.
On the alternate site market we continue to focus in this area
and looking at both the physician market as well as, you know,
the associated surgery center business and long term care so
those are our areas of focus. Outside that is a faster growing
market segment and we look forward to the rewards that is going
to pay us.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 22
Chris McFadden: Jim where would you hope the self manufacturing
penetration rate would be at the, as you exit the fiscal year if
it's 34% in the first quarter?
James Millar: Well I would hope it would be certainly improving. A lot of that
is we've gotten a great deal of the conversion over the past 12
to 15 months of the Bergen acquisition in converting what
we could. That incrementally does grow if we add in new
capabilities, new products, such as bone cement which just
happens to be a new product launch. We have a new
thermal product that is also scheduled to go out in the
marketplace as well. So as we develop new products that helps us.
It's also an issue of we are, we're introducing a new fabric
strategy in our converters line to get really into the nits and
nats that we think is a super homerun. And it's really hard to
speculate as to what the impact is but the customers that have
been testing it for us and as we move this into production here
this quarter have got nothing but super reviews on it. So
(unintelligible).
Chris McFadden: Thank you. Thanks Jim.
James Millar: Okay.
Robert Walter: Next question.
Operator: Your next call comes from Glenn Santangelo of Salomon Smith
Barney.
Glenn Santangelo: Yes Bob thanks. My question revolves around the Pharma
Technologies and Services division, you know, if you could strip
out maybe some of the acquisitions you did in that division if
you could maybe just sort of comment on the organic growth within
that division maybe vis-a-vis some of the bullish comments
you've made recently.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 23
I think if I recall correctly, the guidance was that the business
was going to accelerate, you know, going forward throughout the
year. Maybe what sort of events or milestones should we look for
in that business in order to track the performance as we move
throughout the year.
Robert Walter:Okay George I'm going to ask him to comment on that. Let me first
set it up by saying that we at the Investors Conference, I think
in August he said that we thought the first half would
be slower and accelerate the second half, that we thought the
overall growth rate for the year would be in the 25% range
which Dick confirmed.
Dick also broke out in an effort to make sure you understood
internal growth versus what we call organic growth versus
acquisitions. We reported 16% operating earnings growth. Dick
pointed out that there was a one-time benefit last year in the
same quarter and if you strip that away and take away the
earnings from the two acquisitions, Magellan and Boron
LePore, our internal growth rate was still 16%. So it's
just about a (unintelligible), you know, it kind of sets up to
understand so we're let's talk about around 16% operating growth
in Q1.
George why don't you talk about what you think the events are and
what we're looking forward to for the rest of the year?
George Fotiades:All right the, let me start first with a base business. We said
it's generating 16% growth rates so we're, we feel very good
about the base business particularly some of the key
pharmaceuticals like Kaletra, Zypraxa, (Zalatan), (Deptrol). It's
a good host of strong growth brands that are underpinning the PTS
segment.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 24
The piece that contributes significantly to the 25 plus percent
guidance that we gave that would accelerate in the second half
traces to the launches. They are, the most significant being the
launch of generic Isotretinoin or generic Accutane as well as the
launch of (Clarinexzitis) and Claritin OTC (Zitis). Those were,
the Clarinex and the Isotretinoin in work, when launches that we
had expected to happen earlier in the year. When they weren't
happening that's when we said in our guidance we would still do
25% but these would happen later in the fiscal year rather than
earlier.
With respect to Isotretinoin this is a product that has, was came
generic in February of 2002. We have, it's been at the FDA. We
are through basically the labeling of that product and can, are
able to, once approved be able to ship it with within, have it on
shelves within two weeks.
There's a Citizens Petition that was filed by the originator
earlier this fiscal year. It has to do with patient tracking upon
generic substitution. The FDA cannot approve the ANDA until once
they deal with the Citizens Petition which we would have expected
to have been dealt with by now but frankly hasn't. So we consider
the launch to be imminent but I can't predict the exact time.
Clarinex will, we are confident it will launch for this allergy
season and the Claritin OTC product likewise plans are for it to
launch for this holiday season as well.
So if all these launches happen and there are some others as well
in the sterile side that I can't articulate specifically but are
progressing well, if all those, if all those happen we'll, we
will comfortably meet our guidance.
Glenn Santangelo: Thanks a lot George. I appreciate the comments.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 25
Operator: Your next question comes from Lynn Yaffee of Bank of America.
Lynn Yaffee: Good morning. President Bush proposed some regulations the other
day and I was just wondering if you could discuss them if they
are implemented following the 60-day comment period what effect
you see as that possibly having on your business as it relates to
generics? And are you still finding that the generic business is
significantly more profitable from a gross profit dollar
standpoint as you would have expected?
Robert Walter: The question about the President's announcement on generics we
commented that generics were more profitable to us. We've also
delved in, you know, and shown you a little bit of the effect on
the balance sheet too. As you know we're, you know, a return on
committed capital is an important measurement for our success so
anything that helps generics grow is both good for the consumer
and it's good for us.
On the other hand I wouldn't expect that this is going to have a
major impact upon generic conversions. I think, you know, I mean
as we've pointed out there's a lot of hurdles and legitimate
issues and so I would view this as not exactly a non-event but,
you know, not a major thing that I worried about whether they
were going to get the announcement out yesterday.
With regard to profitability, generics, Jim any comments you
want to make about that?
James Millar: No I think you've said it. More generics is more money for us,
better all the way around.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 26
Robert Walter: As you know in generics we've got a great position and the sense
that, you know, we have bonded with our customer and they've, we
are a collector of buying power and we have the ability to
determine which manufacture or generic product will be used. And
that's why we have that power and we obviously need to pass some
of those advantages on to our customer that, you know, transfers
its purchasing power to us. And so we do that but, so it's
important to our customers that we have a successful generic
program. They do better on margins on generics.
I think I've also said in the past that I believe that the
overall business model not just at retail but at wholesale, the
business model which has to do with the profitability of generics
versus the profitability of branded that the branded
manufacturers travel through our distribution channel too
cheaply and that I think that our profitability will need to be
raised there from branded. But that's a different issue than,
you know, our current profitability in generics.
Lynn Yaffee: Thank you.
Operator: Your next question comes from John Kreger of William Blair.
John Kreger: Thank you. Bob it sounds like the Syncor acquisition is now
about a month away, can you expand a bit on what your
expectations are from that acquisition, what you think it can
really do to expectations both financial and strategically over
the next year or two?
Robert Walter: Okay yes this took us a little bit longer to complete, just to go
through the regulatory processes. As we mentioned we've had,
we've completed the, you know, all the regulatory approvals which
included a review by the SEC of all of our proxy information. So
that's all completed and so this is going to get completed
shortly after the announcement on the 19th.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 27
We've not put out any guidance yet on, any guidance yet on
synergies and things like that for a couple of reasons. First of
all it's a little bit more complicated. As you know that they
have several businesses. They have imaging business and some
international business in addition to their core business which
is nuclear pharmacy.
First of all we fully intend and are marching down the path to
sell other businesses, sell off all other businesses other than
our nuclear pharmacy business and that will happen. Our nuclear
pharmacy businesses are doing extremely well and so as they,
we're already in that business as you know and it is a growth
business with strong returns and we will be the market leader
combining Syncor's business with our business.
And so as a basic business what it does that business is growing,
the, there are now not only diagnostic opportunities but
therapeutic opportunities. I think the most significant strategic
thing, I might let George Fotiades comment on, which is, you
know, where else could we stretch our nuclear pharmacy capability
into in terms of servicing other pharma manufacturers?
George Fotiades:Well if you look their nuclear pharmaceutical business today,
the service they provide, they take a drug that is not quite yet
complete, add value to it just before having to go to the patient
and get it to the market in a short period of time. And if you
take that model to other drug opportunities for example (Zevlon)
which is a nuclear a pharmaceutical from IDEC which again is
one that needed a manufacturing service provided before going to
the patient.
Looking ahead to other biotech or oncology products anything that
would require some form of special handling or pharmacist
intervention or manufacturing intervention or compounding are
are services that these
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 28
pharmacists could uniquely provide on a national basis and
we're the only ones that are in that sort of position to be able
to provide that for specialty pharmaceuticals such as these.
Robert Walter: Okay.
John Kreger: Thank you.
Robert Walter: I think we can, we have time for two more questions if there
are there.
Operator: Your next question comes from Lisa Gill of J.P. Morgan
Securities Incorporated.
Lisa Gill: Thanks very much. Dick I was wondering if you could talk a
little bit about the investment spending. You had said that you
expected it for new product introduction and also what's the
expectation for the year? I think it was about 100 million for
last year and then along those same lines, are we seeing any new
business sign for the New Jersey Development Center? Thanks very
much.
Richard Miller:Okay Lisa our investment spending which includes research and
development, new products, new initiatives, things like that was
about 25 million this quarter. I think we gave guidance that it
would exceed 100 million for the year and I think that's good
news for you all which means we have the earnings capability to
also spend currently funds to produce future results rather than
to just record them as profits for the current quarter. So that's
the range, what we're talking about.
In terms of areas for example Jim mentioned earlier some new
product introductions out in, on our Medical Surgical area that
we're really quite
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 29
excited about. And so you'll, we're going to see the
benefit of that coming in the second half of the year as these
products are launched.
At Pyxis I met with Steve Thomas last night and as you know we
have a new product offering, Patient Station, which is really
both a clinical offering and a patient satisfaction offering at
bedside. We are ramping up on that big time and as Steve's been
talking about the backlog building to that and so I met with them
last night. I said well show me how many people we've got on this
because I'd like to make sure that we're not under-spending here.
As it turns out our development staff for that product line is
actually bigger than the development staff we have for our Supply
Station product line and you know how big we think that is. So I
said, well I'm pleased about that. I guess, you know, when I'm
pleased that we're spending the money to bring product out.
With regard to other initiatives George, any of you want to
comment around PTS?
George Fotiades: I thought Lisa asked about the New Jersey Product Development
Center. It opened in the first quarter. We've started doing
analytical laboratory work. The pilot plant itself that where the
larger money is made opens in late November, early December given
the holiday period. I wouldn't expect that we'd start generating
the real income until we get into the third quarter.
We've integrated that under Magellan. They're bringing their
operating procedures into place there and of course the way they
properly manage pharmaceutical development. So in total today we
now have with Magellan the New Jersey Center, around the world
1100 people, about 10% of PTS's workforce is in upstream
pharmaceutical development.
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 30
The New Jersey Center will still be in an investment mode from a
P&L standpoint for the year and be working it's way just to break
even by the time we get to the end of the year which is I think
incredibly good given the magnitude of what we put in place and
the uniqueness it gives us with respect to the industry.
Lisa Gill: Okay thank you.
Robert Walter: Okay there's time for one more call.
Operator: Your last question comes from John Satter of SG Cowen.
John Satter: Thanks. Bob or Dick I was wondering if you could tell us
if there's been any change in the structure of sourcing deals
with pharma companies and your pharma distribution and
Provider Services segment?
Robert Walter: The question is there any change in our buy in relationship
with pharma manufacturers, is that the question John?
John Satter: Yes really in the structure of the deals. For example maybe
elongated payment terms in exchange for a slightly smaller
size deals.
Robert Walter: I'd, let me just kind of see if I can hit that. I don't, Jim
you want to say anything on it you're welcome but I think overall
I've been saying for 10 years is that how we deal with both our
customer downstream, the provider, and how we deal with the
customer upstream, the pharma manufacturer, changes from quarter
to quarter.
It's built around the fact that we have a key service that we
provide which is logistics, information, buying power, there's
lots of things like that and there's
CARDINAL HEALTH
Moderator: Steve Fischbach
10-22-02/8:30 am CT
Confirmation #5913381
Page 31
unique opportunities that are seasonal or new product
introductions, whatever. So it's always different but I said
earlier that we are in an excellent position in the industry
right now and will be. And so I don't see any significant change
or even meaningful change in our buying relationship with the
pharma manufacturer.
Jim anything you want to add to that?
James Millar: No it's been pretty much the same. The model does shift from time
to time. Terms are not as valuable today as they were at one
point in time. With excess capital or capital readily available
most of these big players are, you know, were cash generators. We
don't need capital so the manufacturer giving us terms, trading
it off in exchange for profits is not as attractive that it might
have once been say 10, 12 years ago when rates were much higher.
But again materially there hasn't been really any significance,
the vendor margin comes to us in a variety of ways and the pharma
manufacturer recognizes that's how we make our money to
facilitate its buy down channel.
John Satter: Great. Thanks a lot guys.
Robert Walter: Okay. Thank you for participating in the call. Obviously we
feel confident about the future and we look forward to
conversations with you all in the next several months and the
call at the end of our second quarter. Thank you.
Operator: Ladies and gentlemen this concludes today's Cardinal Health
first quarter earnings conference call.
END
Except for historical information, all other information in this news release
consists of forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially from those projected, anticipated or implied. The most significant of
these uncertainties are described in Cardinal Health's and Syncor
International's Form 10-K, Form 8-K and Form 10-Q reports and exhibits to those
reports, and include (but are not limited to) the costs, difficulties, and
uncertainties related to the integration of acquired businesses, the pending
acquisition of Syncor by Cardinal Health, the loss of one or more key customer
or supplier relationships, changes in the distribution patterns or reimbursement
rates for health-care products and/or services, the costs and other effects of
governmental regulation and legal and administrative proceedings, and general
economic and market conditions. Cardinal Health undertake no obligation to
update or revise any forward-looking statements.
Information regarding the identity of the persons who may, under SEC rules, be
deemed to be participants in the solicitation of stockholders of Syncor in
connection with the proposed merger, and their interests in the solicitation, is
set forth in a Schedule 14A filed on June 14, 2002 with the SEC. Cardinal Health
has filed a registration statement on Form S-4 in connection with the
transaction, and Syncor has filed and mailed a proxy statement/prospectus to its
stockholders in connection with the transaction. Investors and security holders
of Syncor are urged to read the proxy statement/prospectus because it contains
important information about Cardinal Health, Syncor and the transaction. A free
copy of the proxy statement/prospectus may also be obtained from Cardinal Health
or Syncor at the SEC's Web site at www.sec.gov. Cardinal Health and Syncor and
their respective executive officers and directors may be deemed to be
participants in the solicitation of proxies from the stockholders of Syncor in
favor of the transaction. Information regarding the interests of Syncor's
officers and directors in the transaction is included in the proxy
statement/prospectus. In addition to the registration statement on Form S-4
filed by Cardinal Health in connection with the transaction, and the definitive
proxy statement/prospectus mailed to the stockholders of Syncor in connection
with the transaction, each of Cardinal Health and Syncor file annual, quarterly
and special reports, proxy and information statements, and other information
with the SEC. Investors may read and copy any of these reports, statements and
other information at the SEC's public reference room located at 450 5th Street,
N.W., Washington, D.C., 20549. Investors should call the SEC at 1-800/SEC-0330
for further information. The reports, statements and other information filed by
Cardinal Health and Syncor with the SEC are also available for free at the SEC's
Web site at www.sec.gov. A free copy of these reports, statements and other
information may also be obtained from Cardinal Health or Syncor. Investors
should read the proxy statement/prospectus carefully when it becomes available
before making any voting or investment decision.